Αρχή » Αρχείο κατηγοριών » Επιστημονική Ενημέρωση
EMA suspends Picato as a precaution while review of skin cancer risk continues

EMA suspends Picato as a precaution while review of skin cancer risk continues

On 16 January 2020, EMA recommended that patients stop using Picato (ingenol mebutate), a gel for treating the skin condition actinic keratosis, while it continues its review of the medicine’s safety. EMA’s safety committee (PRAC) is currently reviewing data on skin cancer in patients using Picato. Final results from a study comparing Picato with imiquimod […]

Coronavirus Disease 2019 (COVID-19): Information for Internists

Coronavirus Disease 2019 (COVID-19): Information for Internists

These resources are meant to assist internists seeking to prepare and manage their response. ACP will continue to update this page with resources developed by ACP and other organizations. Read the full article  

Is P2Y12 inhibitor therapy associated with an increased risk of cancer?

Is P2Y12 inhibitor therapy associated with an increased risk of cancer?

Christoph C. Kaufmann, Alexander R. Lyon, Johann Wojta, and Kurt Huber Antiplatelet therapy is a mainstay of cardiovascular therapy and is well established in clinical routine. Recently, the potential risk of solid cancers with P2Y12 inhibitor therapy has been an issue of growing interest. The alleged association primarily originated from the findings of an US […]

Diagnosis of osteoporosis in statin-treated patients is dose-dependent

Diagnosis of osteoporosis in statin-treated patients is dose-dependent

Michael Leutner1, Caspar Matzhold2,3, Luise Bellach1, Carola Deischinger1, Jürgen Harreiter1, Stefan Thurner2,3,4,5, Peter Klimek2,3, Alexandra Kautzky-Willer1 Abstract Objective Whether HMG-CoA-reductase inhibition, the main mechanism of statins, plays a role in the pathogenesis of osteoporosis, is not entirely known so far. Consequently, this study was set out to investigate the relationship of different kinds and dosages […]

Gilenya (φινγκολιμόδη) – Νέα αντένδειξη σε έγκυες γυναίκες και σε γυναίκες σε αναπαραγωγική ηλικία οι οποίες δεν χρησιμοποιούν αποτελεσματική αντισύλληψη. 

Gilenya (φινγκολιμόδη) – Νέα αντένδειξη σε έγκυες γυναίκες και σε γυναίκες σε αναπαραγωγική ηλικία οι οποίες δεν χρησιμοποιούν αποτελεσματική αντισύλληψη. 

  Σε συμφωνία με τον Ευρωπαϊκό Οργανισμό Φαρμάκων (ΕΜΑ) και τον Εθνικό Οργανισμό (ΕΟΦ), η NOVARTIS θα ήθελε να σας ενημερώσει σχετικά με τα παρακάτω: (διαβάστε εδώ ολόκληρη την ανακοίνωση)  

Ενημέρωση για τα φαρμακευτικά προϊόντα που περιέχουν καρβιμαζόλη ή θειαμαζόλη

Ενημέρωση για τα φαρμακευτικά προϊόντα που περιέχουν καρβιμαζόλη ή θειαμαζόλη

Η Uni-Pharma Κλέων Τσέτης Φαρμακευτικά Εργαστήρια ΑΒΕΕ μετά από συμφωνία με τον Ευρωπαϊκό Οργανίσμο Φαρμάκων και τον Εθνικό Οργανισμό Φαρμάκων ενημερώνει τους Επαγγελματίες Υγείας σχετικά με τα φαρμακευτικά προϊόντα που περιέχουν καρβιμαζόλη ή θειαμαζόλη (συνώνυμο: μεθιζόλη): (1) κίνδυνος οξείας παγκρεατίτιδας και (2) ενισχυμένες οδηγίες αντισύλληψης. Μπορείτε να δείτε την επιστολή εδώ.

FDA adds Boxed Warning for increased risk of death with gout medicine febuxostat

FDA adds Boxed Warning for increased risk of death with gout medicine febuxostat

FDA Drug Safety Communication – Safety Announcement The U.S. Food and Drug Administration (FDA) has concluded there is an increased risk of death with Adenuric (febuxostat) compared to another gout medicine, allopurinol. This conclusion is based on our in-depth review of results from a safety clinical trial that found an increased risk of heart-related death and […]

FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions

FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions

The U.S. Food and Drug Administration today is requiring safety labeling changes for a class of antibiotics called fluoroquinolones to strengthen the warnings about the risks of mental health side effects and serious blood sugar disturbances, and make these warnings more consistent across the labeling for all fluoroquinolones taken by mouth or given by injection. […]

EULAR recommendations for the management of antiphospholipid syndrome in adults

EULAR recommendations for the management of antiphospholipid syndrome in adults

Abstract The objective was to develop evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature review and expert opinion, overarching principles and recommendations were formulated and voted. High-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS. Risk modification includes screening […]

Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults

Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults

ABSTRACT Objective To perform a systematic literature review (SLR) informing the European Lmmendations for the management of antiphospholipid syndrome (APS) in adults. Methods A SLR through January 2018 was performed. Research questions were constructed using the Patient, Intervention, Comparator, Outcome (PICO) format. We included data from articles that reported on each relevant intervention. Summary effect […]

Σελίδα 1 of 3123